See you 25-26 Sep in Basel for 24th SACHS Biotech conference
For meetings with CBO, Sarah Holland and CEO, Mads Dalsgaard, please reach out via the partnering system or directly by email/phone.
Oncoteq proud to sponsor Tiffany’s Pink Pedal Ride, for Breast Cancer research
It was a great honor for Oncoteq to sponsor Tiffany’s Pink Pedal Ride, to raise money for the Tiffany Lynn O’Donnell Foundation. The charity event and the funds raised will support Breast Cancer ...
Meeting at J.P. Morgan 2024?
Looking for partnering or investment with Oncoteq? CEO Mads Dalsgaard, CFO Swati Mehta, and CBO Sarah Holland will be attending so please reach out to set up meeting in San Francisco
Oncoteq completes another in-licensing deal, adding a potential best-in-class CD30 antibody drug conjugate from Tubulis to its oncology pipeline
Oncoteq AG (Oncoteq), a clinical stage biotech company specializing in novel and innovative cancer treatments, is expanding its development pipeline by in-licensing the potential best-in-class antibod ...
Oncoteq expands pipeline with TEQ103 , a promising treatment for breast cancer
Today we announce the second in-licensing deal as we obtain a world-wide exclusive license to a novel compound with potential to shift the paradigm in breast cancer treatment. The first-in-class compo ...
Angelo Guainazzi joins Oncoteq as Program Lead
We are very pleased to welcome Angelo Guainazzito the Oncoteq team as Global Program Leader. Angelo brings over a decade of experience in clinical drug development in mainly oncology and neurological ...
Cureteq’s CBO, Sarah Holland, interviewed about career, the role of CBO and Cureteq.
In the latest interview article from Sejelas, Cureteq’s Chief Business Officer, Sarah Holland, shares her career story and her take on the role of Chief Business Officer and about Cureteq.
Steven Mortier joins Oncoteq AG as Global Program Leader
We are pleased to inform you that Steven Mortier is joining us at Oncoteq AG, as Global Program Leader. Steven Mortier brings more than two decades of experience from clinical drug development and pro ...
Sarah Holland appointed as Chief Business Officer
Sarah Holland joins the Cureteq team as Chief Business Officer. Sarah brings over 30 years of biopharma industry experience, spanning the full value chain from R&D, Commercial and Business Develop ...
Cureteq present at the ESMO Conference
Busy and informative days at Conference, ESMO – European Society for Medical Oncology – in Paris; with our sister company and strategic partner Innoplexus.Always motivating to submerge in ...
Cureteq in-licenses oncology asset from Merck KGaA
Cureteq today announces the first of what is planned to be a series of in-licensing deals as the company takes in the compound M8891 from Merck. New development path for M8891 identified with support ...